Trade Summary

Yesterday, Hansen Gwenn, serving as Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 4,111 shares at $24.36 per share, for a total transaction value of $100,141.56. Following this transaction, Hansen Gwenn now holds 117,227 shares of NRIX.

This sale represents a 3.39% decrease in Hansen Gwenn's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, August 4, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, August 5, 2026 at 6:39 AM ET, 1 day after the trade was made.

Nurix Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.